Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation

Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation

LNA-i-miR-221 is a novel microRNA(miRNA)-221 inhibitor designed for the treatment of human malignancies. It has recently undergone phase 1 clinical trial (P1CT) and early pharmacokinetics (PKs) data in cancer patients are now available. We previously used multiple allometric interspecies scaling met...

Full description

Saved in:
Bibliographic Details
Main Authors: Massimiliano Fonsi, Jacques Fulbert, Pierre-Andre Billat, Mariamena Arbitrio, Pierosandro Tagliaferri, Pierfrancesco Tassone, Maria Teresa Di Martino
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Current Research in Pharmacology and Drug Discovery
Subjects:
LNA-I-miR-221
Non-coding RNA
ncRNA
Antisense oligonucleotide
Pharmacokinetic
PK
Online Access:http://www.sciencedirect.com/science/article/pii/S2590257124000245
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2590257124000245

Similar Items